Investment Rating - The report maintains a "Buy" rating for Kunming Pharmaceutical Group [2][6] Core Views - In 2024, the company achieved revenue of 8.401 billion yuan (down 0.34% year-on-year) and a net profit attributable to shareholders of 648 million yuan (up 19.86%) [6] - The acquisition of Huaren Shenghuo is expected to enhance profitability and support the strategic integration of the company's product lines [6] - The stable landing of centralized procurement is anticipated to lead to a recovery in the company's product prices [6] Financial Performance - Revenue and profit forecasts for 2025-2027 are projected at 9.301 billion yuan, 10.102 billion yuan, and 11.041 billion yuan respectively, with net profits of 747 million yuan, 912 million yuan, and 1.135 billion yuan [9] - The company plans to distribute a dividend of 3 yuan per ten shares, resulting in a payout ratio of 35.04% [6] - The gross profit margin is expected to improve from 43.5% in 2024 to 48.2% by 2027 [9] Market Position and Strategy - The company is focusing on brand building and channel development, with significant growth in key products such as "Kunchinese Medicine 1381" and "Shu Gan Granules" [6] - The integration of Huaren Shenghuo is expected to create a benchmark enterprise in the Sanqi industry chain [6] - The company has successfully maintained stable prices for its products under the centralized procurement policy, which is set to last until December 31, 2027 [6]

Investment Rating - The report assigns an "Accumulate" rating to the company [1] Core Views - The company is expected to embrace centralized procurement policies actively, which will enhance its medical terminal coverage and drive future business development [2][4] - The company reported a stable performance in oral medications, while injections saw a significant decline due to policy adjustments [3] - The construction of the Kun Pharmaceutical business model is expected to yield significant results, improving channel efficiency and market reach [5][6] Financial Performance Summary - In 2024, the company achieved a total revenue of 8.401 billion yuan, which is essentially flat year-on-year, while the net profit attributable to shareholders was 648 million yuan, reflecting a 19.86% increase [2][3] - The company forecasts a double-digit revenue growth for 2025, with projected revenues of 9.3 billion yuan and a net profit of 757 million yuan [8] - Key financial metrics for 2024 include a gross margin of 43.5% and a return on equity (ROE) of 12.3% [7] Business Segment Performance - The oral medication segment generated 3.693 billion yuan in revenue, marking an 8.15% year-on-year increase, while the injection segment saw a 49.09% decline, with revenues of 539 million yuan [3] - The blood-activating series products, particularly the oral formulations, showed robust growth, with sales of blood-activating soft capsules reaching 1.584 billion units, a year-on-year increase of 11.27% [3] Strategic Initiatives - The company is actively participating in national and provincial centralized procurement initiatives, which is expected to stabilize product supply prices and enhance market penetration [4] - The Kun Pharmaceutical business model aims to improve the efficiency of distribution channels and increase product accessibility across various medical institutions [5][6]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [11]. Core Insights - The company reported a revenue of 8.40 billion RMB for 2024, a slight decrease of 0.34% year-on-year, while the net profit attributable to shareholders increased by 19.86% to 648 million RMB [1]. - The company is undergoing comprehensive reforms and enhancing its operational systems, which are expected to lead to improved efficiency and sales growth for core products [2]. - The integration with China Resources Sanjiu is showing positive results, with core products anticipated to enter a growth phase due to stable procurement contracts and effective channel management [3]. Summary by Sections Performance Review - In 2024, the company achieved a total revenue of 8.40 billion RMB, reflecting a year-on-year decline of 0.34%. The net profit attributable to shareholders was 648 million RMB, marking a year-on-year increase of 19.86% [1]. - The adjusted net profit for Q4 2024 was approximately 130 million RMB, significantly improving from 25 million RMB in Q4 2023 [1]. Operational Analysis - The company is implementing a 4C operational system to enhance organizational efficiency and talent management, aiming for a more integrated structure [2]. - The company has successfully renewed procurement contracts for its core products, with expectations for increased market penetration and sales volume [2]. - Key products such as Shenling Baizhu Powder and Shugan Wan have shown a combined revenue growth of 20%, with one product surpassing 100 million RMB in revenue [2]. Profit Forecast, Valuation, and Rating - The company is projected to achieve net profits of 740 million RMB, 893 million RMB, and 1.07 billion RMB for the years 2025, 2026, and 2027, respectively, with growth rates of 14%, 21%, and 20% [3]. - The earnings per share (EPS) are expected to be 0.98 RMB, 1.18 RMB, and 1.42 RMB for the same years, with corresponding price-to-earnings (P/E) ratios of 18, 15, and 13 [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [11]. Core Insights - The company reported a revenue of 8.40 billion RMB for 2024, a slight decrease of 0.34% year-on-year, while the net profit attributable to shareholders increased by 19.86% to 648 million RMB [1]. - The company is undergoing comprehensive reforms and enhancing its operational systems, aiming for a more efficient and integrated organization [2]. - The company’s core products are expected to see increased sales due to stable contract renewals in national traditional Chinese medicine procurement [2]. - The company’s net profit forecasts for 2025-2027 are 740 million RMB, 893 million RMB, and 1.07 billion RMB, reflecting year-on-year growth rates of 14%, 21%, and 20% respectively [3]. Summary by Sections Performance Review - In Q4 2024, the company achieved a non-deductible net profit of approximately 130 million RMB, a significant improvement from 25 million RMB in Q4 2023 [1]. - The company’s revenue growth rate is projected to be 9.07% in 2025, with a steady increase in net profit margins [6]. Operational Analysis - The company is focusing on channel reforms and enhancing distributor management, which is expected to support the growth of core product sales [2]. - The integration of Huaren Shenghuo is anticipated to strengthen the company’s market position and product offerings [2]. Profit Forecast and Valuation - The earnings per share (EPS) for 2025-2027 are projected to be 0.98 RMB, 1.18 RMB, and 1.42 RMB, with corresponding price-to-earnings (P/E) ratios of 18, 15, and 13 [3]. - The company is expected to enter a new growth phase in 2025, driven by the successful implementation of its channel reforms and the anticipated increase in sales volume of core products [3].

Group 1: Banking Sector Insights - The quantitative backtest results indicate that undervalued strategies contribute to excess returns while effectively reducing drawdowns [1] - High ROE and the strategy based on "provision coverage ratio - non-performing loan ratio - attention ratio" show superior performance, while short-term improvement strategies underperform [1] - The combined strategy of high ROE/PB and high "provision coverage ratio - non-performing loan ratio - attention ratio" × dividend yield has achieved over 300% cumulative excess returns since 2011, highlighting the importance of quality and value in bank stock investments [1] Group 2: Dividend Strategy Analysis - Current dividend strategies exhibit significant bottom characteristics, with a rare "negative return - high volatility" feature over the past three months, indicating potential for recovery [2] - The 40-day excess return of dividends is nearly -10% below the annual average, suggesting a high probability of excess return reversion based on historical patterns [2] - The dividend ETF is in a net subscription state with reduced trading volume, typically corresponding to a bottom phase for the strategy [2] Group 3: Copper Industry Outlook - The expectation of increased tariffs on imported copper in the U.S. is likely to push copper prices back to peak levels, with COMEX copper prices reaching new highs compared to LME prices [3] - The tariff impact on domestic demand in China is expected to be limited, but it may restrict imports of refined copper and scrap copper [3] - Positive policy developments and market dynamics are expected to accelerate the convergence of trading and fundamental factors, leading to a bullish outlook for copper prices [3] Group 4: Quantitative Strategy Improvements - The traditional asset rotation framework has been improved to address issues such as low flexibility and fixed scoring standards, enhancing the model's comprehensiveness and adaptability [4] - The industry rotation model constructed from 26 indicators achieved a 32% annualized absolute return during the backtest period from 2017 to January 2025, outperforming the Shanghai and Shenzhen 300 index [5] Group 5: U.S. Stock Market Strategy - U.S. stock markets are experiencing downward pressure due to uncertainties surrounding Trump's policies and tariffs, with major indices giving back all gains since the Fed's rate cuts in September 2023 [7] - Economic indicators from the U.S. have underperformed expectations, and trade tensions may further weaken the economic fundamentals, leading to capital rotation out of U.S. equities [7] - The outlook for U.S. stocks is expected to remain volatile until late March or early April, with recommendations to focus on healthcare, consumer services, traditional telecommunications, and utilities sectors [7] Group 6: Bond Market Insights - The demand for bond ETFs is increasing due to heightened market volatility, offering investors a more convenient and diversified investment tool compared to traditional bond allocations [8] - Local government bond ETFs are noted for their potential yield enhancement and better drawdown control compared to other bond ETF types [8] Group 7: Magnesium Alloy Market Potential - The demand for magnesium alloys in China is expected to grow due to rich domestic magnesium production and the lightweighting needs in automotive and robotics sectors [10] - The semi-solid magnesium alloy forming technology is anticipated to open new growth avenues for leading companies in the industry [10] Group 8: Dairy Industry Forecast - The potential implementation of child-rearing subsidies by 2025 may improve birth rates, positively impacting the demand for infant formula and cheese products [11] - The expected increase in the population of children aged 0-6 years is likely to boost the market outlook for children's cheese products [11]

结构性分化，把握龙头配置价值 ——中药行业2025年2月月报 长城证券产业金融研究院 分析师：刘鹏 执业证书编号：S1070520030002 邮箱：liupeng@cgws.com 分析师：袁紫馨 执业证书编号：S1070122080041 邮箱：yuanzixin@cgws.com 评级：强大于市（维持） 2025.03.03 01 核心观点 核心观点 1、 2024年 中 药 行 业分 化加大 ，头部 效应凸 显，竞 争格局 有望重 塑 2024年多因素影响行业竞争局，头部企业优势集中，华润系（华润三九、东阿阿胶、昆药集团、江中药业）、片仔癀名贵 OTC龙头、 奇 正藏药 院内贴 膏龙头 通过品 牌壁垒 和渠道 优势普 遍实现 稳健增 长，中 小企业 受成本 端压力 、集采 政策、 医保控 费、消费 疲软等 因素共 振 陷 入 亏 损 或利润 同比下 滑，行 业整体 承压， 2025年 业 绩 压 力减弱 下弹性 有望释 放 2、 估 值 与复盘 • 2月中药板块下跌1.15%， 大 幅 跑输 沪深300和 SW 医 药 生 物指数 ，主要 系科技 成长股 资金虹 吸效应 及"AI+医 疗" 关 注 景 ...

Summary of China Resources Sanjiu's Conference Call Company Overview - **Company**: China Resources Sanjiu - **Industry**: Pharmaceutical and Health Products Key Financial Performance - Revenue growth from 13.6 billion to 24.7 billion from 2020 to 2023, with a compound annual growth rate (CAGR) of 19% [3] - Net profit increased from 1.6 billion to 2.85 billion during the same period, with a CAGR of 21% [3] - For the first three quarters of 2024, revenue reached 19.7 billion and net profit was 2.96 billion [3] Core Business and Market Performance - Core businesses include Consumer Health Care (CHC) and Prescription Drugs (RIX) [4] - CHC revenue grew from 7.56 billion to 11.7 billion from 2019 to 2023, with a CAGR of 12%, accounting for 52% of total revenue in the first half of 2024 [4] - The leading product, 39 Cold Granules, achieved a market share of 23% with retail sales of 3.08 billion in 2023 [5] Research and Development (R&D) Investment - R&D investment increased from 530 million to 890 million from 2019 to 2023, with a CAGR of 14% [6] - R&D personnel grew from over 400 to 778, with a CAGR of 18% [6] - 112 ongoing projects focused on oncology, orthopedics, and other therapeutic areas [6] Mergers and Acquisitions - Significant acquisitions include Kunming Pharmaceutical Group and Tianjin Tasly, enhancing product lines and capabilities in cardiovascular fields [7] - The acquisition of Kunming Pharmaceutical significantly contributed to the company's traditional Chinese medicine segment [7] Shareholder Returns - Increased dividend payout ratio, with 2021 dividends at 8.6 per 10 shares, maintaining above 10 per 10 shares thereafter [8] - Implementation of an equity incentive plan to motivate mid-to-senior management [8] Future Development Strategy - Focus on both organic growth and strategic acquisitions to enhance market share [9] - Increased R&D investment to strengthen innovation capabilities [9] Prescription Drug Business Outlook - Prescription drug revenue declined by 13.2% to 5.2 billion in 2023 due to regulatory changes and procurement policies [12] - The company aims to recover through innovation and cost management strategies [12] Financial Projections - Expected revenue growth of over 10% from 2024 to 2026, with net profits projected at 3.37 billion, 3.84 billion, and 4.35 billion respectively [14] - Earnings per share (EPS) forecasted at 2.62, 2.99, and 3.39 for the same period [14] Valuation and Risks - Target price set at 56.8 based on a 19x PE ratio for 2025 [15] - Risks include intensified market competition, integration challenges, goodwill impairment, and uncertainties from procurement policies and raw material price fluctuations [15]

Market Review - The overall market sentiment for the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index declining by 2.78%, underperforming the CSI 300 Index by 0.56 percentage points, ranking 21st among 30 primary industries [4] - The top ten stocks by growth this week include Nuo Cheng Jian Hua-U, Chang Yao Holding, and Shanghai Yi Zhong, with growth rates of 20.98%, 20.96%, and 18.78% respectively [3][4] - Conversely, the bottom ten stocks include Jiangsu Wu Zhong and Xin Gan Jiang, with declines of 4% and 6% respectively [4] Industry and Stock Events - The pharmaceutical sector's valuation is currently low, with public funds (excluding pharmaceutical funds) also underweight in this sector. The outlook for the pharmaceutical industry in 2025 remains optimistic due to macroeconomic factors such as the recovery of US Treasury yields and the driving effect of large categories and products [7] - In the innovative drug segment, there is a shift from quantity logic to quality logic, emphasizing the importance of product differentiation and internationalization. Companies to watch include Heng Rui, Bai Ji, and Nuo Cheng Jian Hua [7] - The medical device sector is expected to benefit from the acceleration of equipment renewal policies, with key companies like Mai Rui Medical and Xin Hua Medical positioned to gain from increased orders [7] - The IVD market is anticipated to return to high growth, with a focus on companies like An Tu Biology and Di Rui Medical, as domestic market penetration continues to expand [7] - The blood products sector is set for growth, with a favorable regulatory environment for plasma collection and increasing demand post-pandemic. Companies such as Tian Tan Biology and Bo Ya Biology are recommended [12] Antibiotics Industry Update - The global antibiotic market is projected to grow steadily, with a market size of approximately 98 billion yuan in China from 2017 to the third quarter of 2024. The top three hospital antibiotics in 2024 are expected to be injectable formulations of Piperacillin and Tazobactam, with sales of 4.94 billion yuan [15][16] - The production capacity for key antibiotic intermediates is under strict regulatory control, with the latest guidelines from the National Development and Reform Commission continuing to restrict new capacity in antibiotic intermediates [17] - The price trends for key antibiotic products such as Penicillin and 6-APA have shown fluctuations, with 6-APA's price reaching 320 yuan per kilogram by January 2025 [24][25]

Investment Rating - The report maintains a strong investment rating for the biopharmaceutical industry, particularly for the traditional Chinese medicine (TCM) sector, which is expected to benefit from multiple factors in 2025 [2]. Core Insights - The TCM sector is anticipated to experience a gradual reduction in performance pressure in 2025, driven by factors such as improved earnings, favorable policies, decreasing costs, rising demand, and consolidation within the industry [4][6]. - The report identifies five main investment opportunities within the TCM sector, including high-end OTC products, state-owned enterprise reforms, hospital-based TCM, dividend-paying assets, and turnaround situations for struggling companies [4][7]. Summary by Sections 1. Performance Outlook - The TCM sector faced overall revenue decline in 2024, with a total revenue of 270.61 billion yuan, down 3.28% year-on-year, and a net profit of 29.88 billion yuan, down 8.55% year-on-year [10]. - The number of companies forecasting negative net profit growth in 2024 is 22 out of 34, while only 12 companies expect positive growth [16]. 2. Policy Developments - The third batch of national TCM procurement results showed an average price reduction of 63%, but the impact on listed companies is limited due to the small number of affected products [20]. - A new essential drug list is expected to be released in 2025, which may include more TCM products, enhancing their market presence [24]. 3. Cost Factors - The TCM material price index has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies and improve their gross margins starting in 2025 [28]. 4. Demand Dynamics - The recent increase in flu cases has driven demand for related treatment products, leading to a quicker clearance of inventory for cold and cough medications [34]. 5. Competitive Landscape - The TCM industry is experiencing frequent mergers and acquisitions, which are likely to enhance industry concentration and provide performance flexibility for related listed companies [39]. 6. Investment Opportunities - The report highlights five key investment themes: 1. High-end OTC TCM products, particularly those using natural bezoar as a key ingredient, are expected to see improved margins as supply stabilizes [45][54]. 2. State-owned enterprise reforms are anticipated to yield positive changes in management and strategic planning [7]. 3. Hospital-based TCM products are expected to gain market share due to regulatory support [7]. 4. Companies with strong cash flow and high dividend potential are viewed favorably [7]. 5. Companies currently facing challenges are expected to improve as inventory pressures ease [7]. 7. Recommended Stocks - The report suggests monitoring companies such as Kunming Pharmaceutical, Tongrentang, Darentang, Jiangzhong Pharmaceutical, Dong'e Ejiao, China Resources Sanjiu, Yunnan Baiyao, Tianshili, Fangsheng Pharmaceutical, and others for potential investment opportunities [4].

Investment Rating - Industry rating: "Overweight" (maintained) [2] Core Views - The market performance of traditional Chinese medicine (TCM) sector shows a 0.8% increase last week, while the overall pharmaceutical sector continues its rebound [1][4] - The expansion of grassroots TCM services is expected to drive demand growth, with the number of TCM clinics increasing from over 3,000 in 2015 to 42,000 in 2024, achieving nearly full coverage in community health service centers and township hospitals [8] - The TCM sector is experiencing a dual scenario of price governance and consumer recovery, presenting both pressures and opportunities [9] Summary by Sections Market Performance - Last week, the TCM index closed at 6446.65 points, up 0.8%, while the pharmaceutical sector index rose to 7368.1 points, an increase of 2.71% [4][14] - The relative performance of TCM compared to the CSI 300 index shows a decline of 2% over the past month and 17% over the past year [3][4] Valuation - The TCM sector's PE (ttm) is 26.87X, up 0.22X week-on-week, with a one-year maximum of 30.13X and a minimum of 22.58X. The PB (lf) is 2.32X, also up 0.02X week-on-week, with a one-year maximum of 2.65X and a minimum of 1.99X [6] - The TCM sector has a valuation premium of 110.86% compared to the CSI 300 index [6] Upstream TCM Materials - The TCM materials price index decreased slightly to 255.65 points, down 0.2% week-on-week, influenced by the Spring Festival market closure [7] Investment Suggestions - The report suggests focusing on companies with strong R&D capabilities and unique products that can benefit from price governance and consumer recovery [9][10] - Key investment themes include price governance, consumer recovery, and state-owned enterprise reform, with recommendations to pay attention to companies with strong brand power and product advantages [11]